3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
136
Parkinson Disease 4, Autosomal Dominant Lewy Body
122
Melanoma
94
Neoplasms
74
Squamous Cell Carcinoma of Head and Neck
65
Colorectal Neoplasms
42
Triple Negative Breast Neoplasms
38
Carcinoma, Renal Cell
37
Lung Neoplasms
36
Head and Neck Neoplasms
34
Breast Neoplasms
34
Stomach Neoplasms
33
Neoplasm Metastasis
32
Carcinoma, Hepatocellular
32
Urinary Bladder Neoplasms
31
Pancreatic Neoplasms
30
Ovarian Neoplasms
29
Carcinoma, Transitional Cell
25
Endometrial Neoplasms
19
Recurrence
16
Sarcoma
15
Esophageal Neoplasms
15
Carcinoma
15
Uterine Cervical Neoplasms
14
Prostatic Neoplasms
14
Small Cell Lung Carcinoma
13
Lymphoma
13
Fallopian Tube Neoplasms
13
Carcinoma, Squamous Cell
13
Lymphoma, Non-Hodgkin
12
Interventions
Fluorouracil
2
Docetaxel
2
thymoglobulin
1
temsirolimus
1
sargramostim
1
pirarubicin
1
pembrolizumab
1
pazopanib
1
fludarabine phosphate
1
fludarabine
1
cc-486
1
X-Rays
1
Whole-Body Irradiation
1
Trastuzumab
1
Tacrolimus
1
Surveys and Questionnaires
1
Rituximab
1
Radiotherapy
1
Proctectomy
1
Pemetrexed
1
Oxaliplatin
1
Mycophenolic Acid
1
Monatide (IMS 3015)
1
Metformin
1
Melphalan
1
Leucovorin
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Epirubicin
1
Drug Therapy
1
Diphenhydramine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Pathologic Complete Response
×
pembrolizumab
×
Clear all
NCT04435197
2024-07-03
PALACE-2
Ruijin Hospital
Phase 2
Completed
143 enrolled